HKU Scholars Hub: Browsing DSpace

Browsing by Author McNally, J

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 2 to 5 of 5 < previous

	Title	Author(s)	Issue Date	Views
	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection Journal:New England Journal of Medicine	Feld, JJ Jacobson, IM Hézode, C Asselah, T Ruane, PJ Gruener, N Abergel, A Mangia, A Lai, CL Chan, HLY Mazzotta, F Moreno, C Yoshida, E Shafran, SD Towner, WJ Tran, TT McNally, J Osinusi, A Svarovskaia, E Zhu, Y Brainard, DM McHutchison, JG Agarwal, K Zeuzem, S	2015	110
	Sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in genotype 1, 2, 4, 5, 6 HCV patients: ASTRAL-1 study Proceeding/Conference:Hepatology International	Chan, HLY Feld, JJ Agarwal, K Hezode, C Asselah, T Ruane, PJ Gruener, N Abergel, A Mangia, A Lai, CL Mazzotta, F Moreno, C Yoshida, E Shafran, SD Towner, WJ Tran, TT McNally, J Brainard, DM Jacobson, IM Zeuzem, S	2016	68
	Sofosbuvir/Velpatasvir fixed dose combination for 12 weeks in hcv infected patients previously treated with placebo: results of the deferred treatment study (GS-US-342-1446 Study) Proceeding/Conference:Journal of Hepatology	Asselah, T Shafran, S Bourgeois, S Lai, CL Cramp, M Mathurin, P Willems, B Nguyen, MH Davis, MN Huang, KC Svarovskaia, E Osinusi, A Mcnally, J Brainard, D McHutchison, J Shaikh, OS Tran, TT	2016	55
	Sofosbuvir/velpatasvir for 12 weeks results in high SVR12 rates with a favorable safety profile in asian patients: an integrated subgroup analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies Proceeding/Conference:Hepatology International	Chan, HLY Lai, CL Feld, J Reau, N Han, L McNabb, BL McNally, J Brainard, DM Foster, G Roberts, S	2017	94

Showing results 2 to 5 of 5 < previous